Sign In
Buy MRNA
$51.59
+2.53 (+5.16%)
At Close: Jun 04, 2026
COVID-19 Vaccine Maker Moderna Faces Patent Infringement Suit
05:23pm, Monday, 28'th Feb 2022 IBTimes
Arbutus Biopharma Corp. and Genevant Siences allege in their complaint that Moderna infringed on patents they held to develop the COVID-19 vaccine.
Biotech firms allege Moderna hijacked technology to develop COVID-19 vaccine
05:12pm, Monday, 28'th Feb 2022 The Hill
Two biotech companies filed a lawsuit against Moderna on Monday, alleging that the vaccine manufacturer had infringed on patented technology when it developed its COVID-19 vaccine.Arbutus Biopharma and Genevant Sciences allege in their civil…
Arbutus files patent infringement lawsuit against Moderna related to COVID shot
04:22pm, Monday, 28'th Feb 2022 Reuters
Arbutus Biopharma Corp said on Monday it had filed a lawsuit against Moderna Inc seeking damages for infringement of U.S. patents related to Moderna''s COVID-19 vaccine.
Arbutus Hits Moderna With New Suit Claiming COVID-19 Vaccine Patent(s)
03:22pm, Monday, 28'th Feb 2022 Benzinga
Arbutus Biopharma Corporation (NASDAQ: ABUS ) and Genevant have sued Moderna Inc (NASDAQ: MRNA ) for infringing on their patent on a lipid nanoparticle platform that they say was crucial to the delivery of Moderna’s widely-used COVID-19 vaccine. The companies are seeking an award of damages sufficient to compensate Arbutus and Genevant for Moderna’s infringement under 35 U.S.C. §284, in no event less than a reasonable royalty on all infringing sales or other dispositions of Accused Product. Moderna tried to preempt a lawsuit by asking federal courts to block certain Arbutus patents, but the U.S. Court of Appeals for the Full story available on Benzinga.com
Moderna Faces Patent Lawsuit on Covid-19 Vaccine
03:01pm, Monday, 28'th Feb 2022 Barron''s
Two small firms say their patents cover the lipid nanoparticle wrappers used to carry the messenger RNA in Moderna’s vaccine through the bloodstream and into the cells.
MRNA stock lower as Arbutus, Genevant seek damages for vaccine patents (NASDAQ:ABUS)
11:56am, Monday, 28'th Feb 2022 Seeking Alpha
The clinical-stage biopharma company Arbutus Biopharma (ABUS) and Genevant Sciences has filed a lawsuit on Monday against Moderna (MRNA) and an affiliate of the biotech seeking damages…
Arbutus files patent infringement lawsuit against Moderna By Reuters
11:56am, Monday, 28'th Feb 2022 State Of Press
© Reuters. FILE PHOTO: Boxes containing the Moderna COVID-19 vaccine are prepared to be shipped at the McKesson distribution center in Olive Branch, Mississippi, U.S. December 20, 2020. Paul Sancya/Pool via REUTERS/File Photo (Reuters) – Arbutus Biopharma (NASDAQ:) Corp said on Monday it had filed a lawsuit against Moderna (NASDAQ:) Inc seeking damages for infringement …
Arbutus files patent infringement lawsuit against Moderna
11:34am, Monday, 28'th Feb 2022 Reuters
Arbutus Biopharma Corp said on Monday it had filed a lawsuit against Moderna Inc seeking damages for infringement of patents related to its COVID-19 vaccine.
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna
11:02am, Monday, 28'th Feb 2022 GlobeNewswire
WARMINSTER, Pa., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and Genevant Sciences today filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna, Inc. (Nasdaq: MRNA) and a Moderna affiliate seeking damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna’s vaccine for COVID-19. The patents relate to nucleic acid-lipid particles and lipid vesicles, as well as compositions and methods for their use. The filed complaint is available on the Arbutus website .
Genevant Sciences and Arbutus Biopharma File Patent Infringement Lawsuit Against Moderna
11:01am, Monday, 28'th Feb 2022 GlobeNewswire
VANCOUVER, British Columbia and CAMBRIDGE, Mass. and BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company, and Arbutus Biopharma Corporation (Nasdaq: ABUS) today filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna, Inc. (Nasdaq: MRNA) and an affiliate seeking damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of mRNA-1273, Moderna’s vaccine for COVID-19. The patents relate to nucleic acid-lipid particles and lipid vesicles, as well as compositions and methods for their use. The filed complaint is available at https://investor.roivant.com/news-events/events .
Moderna faces new lawsuit over lucrative coronavirus vaccine
11:00am, Monday, 28'th Feb 2022 The Washington Post
The suit is the second patent fight over the development of the messenger RNA shot.
This Is Why Moderna May Crush Its Vaccine Rivals
11:00am, Monday, 28'th Feb 2022 The Motley Fool
It has to do with technology -- and one particular service.
Moderna posts $18bn profit for 2021 amid calls for patent waiver
08:39am, Monday, 28'th Feb 2022 BusinessDay
Moderna has posted $18.5 billion revenue from COVID-19 vaccine sales in the 2021 full year amid growing calls for manufacturers to waive intellectual property rights to help developing countries jumpstart local vaccine production. The US biopharmaceutical company expects to hit a total of $22 billion this year, after reporting fourth-quarter earnings that beat earnings and […]
This 1 Number Could Mean Billions for Moderna Over the Long Term
11:15am, Sunday, 27'th Feb 2022 The Motley Fool
And it isn''t related only to the coronavirus vaccine.
Could Moderna Be the Perfect Stock to Buy in a Market Correction?
10:56am, Sunday, 27'th Feb 2022 The Motley Fool
Here are five reasons why Moderna could be just what investors need during this stock market pullback.
